Gordon Van Slyke: A Trial Participant’s Inside Look at New Alzheimer’s Drug Leqembi

When Gordon Van Slyke, 75, decided to participate in the phase drug trials for Eisai and Biogen’s new monoclonal antibody drug Leqembi (lecanemab), it was his family history with Alzheimer’s that motivated him.
We rely on donations to bring you the latest research on dementia and brain health and to support our amazing team of independent journalists. Please consider donating to support of our mission of giving people impacted by dementia a better resource and connection to experts at the forefront of research. Our audience has grown so rapidly; we have exciting plans for the future to enhance our coverage even further but we need your help. Please consider making a contribution to help fund Being Patient's editorial costs.
beingpatient.n...
---------------------------------------------------------------------------------------------------------------
Stay connected on social media:
To catch our Brain Talks live, join our Facebook page:
/ beingpatient. .
To learn more about us, follow us on Instagram:
@beingpatientvoices
For the latest news on dementia research and lifestyle tips, visit our site:
www.beingpatie...

[@7113cole]

Gordon, you Sir are a hero. Thank you for volunteering to be a part of this study.❤

[@vickierabalais3574]

Very helpful interview, and God bless this good man!